Industries > Pharma > Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029

Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029

North America, Europe, India, Rest of the World (RoW)

PUBLISHED: 29 January 2019
PAGES: 207
PRODUCT CODE: PHA0352
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0352 Categories: , Tag:

The top 10 generic drug producers have 61% share of the total revenue made by these top 50 companies. 22% of the top 50 generic drug producers are in North America. 30% of the top 50 generic drug producers fall under the RoW region. This figure reflects the increasing penetration of generics on a global scale with many pharmaceutical companies realising this industry as a primary source of revenue.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 207-page report you will receive 74 tables and 72 figures– all unavailable elsewhere.

The 207-page report provides clear detailed insight into the top 50 generic drug producers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017.

• Our report assesses the leading generic drug manufacturers worldwide. In general a company profile gives you the following information:
• Discussion of activities, technologies and recent financial results
• Assessment of developments – mergers and acquisitions (M&A), new products, outlooks, challenges and plans
• Historical revenue ($) and CAGR (%) of top players
• Forecasting of generic drug revenues to 2029 (for 18 leading companies).

• This report discusses the factors that affect the industry:
• M&A activity and related partnerships
• Global and regional strategies – extending business reach
• Competition from companies based in emerging national markets
• Increasing specialisation by leading players, including big pharma companies
• Increasing consolidation of the generics industry
• Advances in production technologies, including difficult-to-make generics and biosimilars – important shifts and opportunities in the industry.

• This report analyses the leading generic drug manufacturers in North America, including these companies:
• Abbott
• Akorn
• Alvogen
• Endo
• Impax
• Mallinckrodt
• Mylan
• Pfizer
• Pharmascience
• Valeant

• This report analyses the leading generic drug manufacturers in Europe, including these companies:
• Fresenius Kabi
• Gedeon Richter
• Insud Pharma
• Krka
• Novartis (Sandoz)
• Perrigo
• Pharmstandard
• Polpharma
• Sanofi
• Stada Arzneimittel

Top Generic Drug Producers Market Forecast 2019-2029

• This report analyses the leading generic drug manufacturers in India, including these companies:
• Sun Pharmaceuticals
• Aurobindo
• Lupin
• Cipla
• Dr Reddy’s
• Glenmark
• Torrent Pharma
• Cadila
• Wockhardt
• Ipca

• This report analyses the leading generic drug manufacturers in RoW, including these companies:
• Teva
• EMS
• Aspen
• Sawai Pharmaceutical
• Nichi-Iko
• Abdi Ibrahim
• Towa Pharmaceutical
• Eurofarma
• Taro Pharmaceutical
• Hypermarcas

Visiongain’s study is intended for anyone requiring commercial analyses for the top generic drug manufacturers. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029: North America, Europe, India, Rest of the World (RoW).

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview
1.1 Global Top Generic Drugs Producers Market Introduction
1.2 Overview of Findings
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Top 50 Generic Drug Manufacturers
2.1 Top 50 Generic Drug Manufacturers: Revenues and Ranking, 2017
2.2 Top 50 Generic Drug Companies: Revenue Analysis, 2017
2.3 Top 50 Generic Drug Companies Regional Distribution, 2017
2.4 Report Coverage
2.5 Report Complexity
2.5.1 Obtaining Data from Private Companies
2.5.2 Financial Years Variability
2.5.3 Generics Revenue Identification
2.5.4 Defining Generics 1: Difference Between Biosimilars and Generics
2.5.5 Defining Generics 2: ‘Super-Generics’ and APIs
2.5.6 Defining Generics 3: Rx and OTC

3. Top North American Generic Drug Manufacturers: Activities and Prospects, 2017-2029
3.1 Companies Covered in this Chapter
3.2 Leading North American Generic Drug Manufacturers: Financial Performance Outline, 2017
3.3 Mylan: Largest North American Manufacturer of Generic drugs, 2017
3.3.1 Mylan Historical Performance and Financial Results Analysis, 2017
3.3.2 Mylan Generic Drugs Revenue Forecast, 2017-2029
3.3.3 First Class II Transdermal Approval Consolidates Mylan’s Top Status in the US Market
3.3.4 Mylan’s European Portfolio is Diversifying
3.3.5 Mylan’s Generic Portfolio Remains the Company’s Core Strength
3.3.6 Mylan’s Winning Acquisition Strategy
3.4 Pfizer – The Leading Research-Based Pharmaceutical: Company Overview, 2017
3.4.1 Pfizer Historical Performance and Financial Results Analysis, 2017
3.4.2 Pfizer Generic Drugs Revenue Forecast, 2017-2028
3.4.3 Pfizer Internationalization and Restructuring Strategy
3.4.4 Pfizer’s Acquisition of Hospira: Has it Boosted Revenue from Generics?
3.4.5 Prospects for Pfizer’s Generic Drugs Business
3.5 Abbott: Company Overview, 2017
3.5.1 Abbott Business Segments Performance
3.5.2 Abbott Historical Performance and Financial Results Analysis, 2017
3.5.3 Abbott Generic Drugs Revenue Forecast, 2017-2029
3.5.4 Abbott’s Acquisitions: Overview and Analysis, 2010-2018
3.5.5 Abbott’s Sale of its Overseas Branded Generic Business: Implications
3.5.6 Future Prospects for Abbott Generic Drugs Business
3.6 Apotex – The Largest Pharmaceutical Company in Canada: Company Overview, 2017
3.6.1 Apotex Expansion to Europe and Beyond
3.6.2 Apotex Announces $184 Million US Expansion Move for 2017
3.7 Endo Pharmaceuticals: Company Overview, 2017
3.7.1 Endo: Divests to Specialise in Generics
3.7.2 Endo Reducing Presence on the South African Market
3.7.3 Performance Analysis on Endo’s US Generic Pharmaceuticals Segment
3.7.4 Future Prospects for Endo Pharmaceuticals Generic Drugs Business
3.7.5 Endo Generic Drugs Revenue Forecast, 2017-2029
3.7.6 Par Pharmaceuticals: Merged with Endo Qualitest: Company Overview, 2017
3.7.7 Par Pharmaceuticals’ Acquisition of JPH Group Holdings
3.7.8 Concentrated Generic Revenue Stream and Over 60 Generic Prescription Drugs
3.7.9 Buy Out of Indian Ethics Bio Lab Demonstrates Par’s Interest in Niche Products
3.8 Valeant Pharmaceuticals: Company Overview, 2017
3.8.1 Valeant: A Major Challenger in the Emerging Markets
3.8.2 Valeant Generic Drugs Revenue Forecast, 2017-2029
3.9 Pharmascience - Another Major Canadian Player: Company Overview, 2017
3.9.1 Over 200 Generic Product Families
3.9.2 Korean Venture Driving Diversification for Pharmascience
3.10 Mallinckrodt: Company Overview, 2017
3.10.1 Mallinckrodt Generics: Valuable Addition to the Company’s Portfolio
3.10.2 Reclassification of Methylphenidate ER Products: Effects on Mallinckrodt’s Income
3.10.3 What is Mallinckrodt’s Advantage Against Strong Competition?
3.10.4 Partnerships and Acquisitions: Crucial for Mallinckrodt’s Rapid Expansion
3.11 Akorn Pharmaceuticals: Company Overview, 2017
3.11.1 Akorn Acquisition of Small Companies: A Strategic Shift Towards Broad Market Reach
3.11.2 Akorn Strengthens its Position on the US Ophthalmology Market
3.12 Alvogen is a Privately-Owned US Company and the One to Watch: Company Overview, 2017
3.12.1 Alvogen Unique Business Model Proves Good Results
3.12.2 Alvogen Target is to Become Top 10 Global Generic Player
3.13 Impax Laboratories: A New Entrant on the Visiongain US List, Company Overview 2017
3.13.1 Generic Revenues Decrease in 2017 for Impax

4. Top European Generic Drug Manufacturers: Activities and Prospects, 2017-2029
4.1 Companies Covered in this Chapter
4.2 Leading European Generic Drug Manufacturers: Financial Performance Outline, 2017
4.3 CEE Markets Home to Many Big Generic Contenders
4.4 Novartis (Sandoz) - the World’s Second Largest Generic Pharmaceutical Company: Overview, 2017
4.4.1 Novartis (Sandoz) Historical Performance and Financial Results Analysis, 2017
4.4.2 Novartis (Sandoz) Generic Drugs Revenue Forecast, 2019-2029
4.4.3 Novartis (Sandoz) Key Developments Analysis, 2017
4.4.4 Emphasis on Complex, Differentiated Generics and Biosimilars
4.4.5 Future Prospects for Novartis Generic Drugs Business
4.5 Sanofi: Company Overview, 2017
4.5.1 Sanofi Historical Performance and Financial Results Analysis, 2017
4.5.2 Sanofi Generic Drugs Revenue Forecast, 2019-2029
4.5.3 Sanofi Announces Intentions to Divest European Generics Business
4.5.4 Future Prospects for Sanofi’s Generic Drug Business
4.6 Fresenius Kabi - Leading Generic Intravenous Drug Player: Company Overview, 2017
4.6.1 Intra Venous Drugs: The Main Product Line for Fresenius Kabi
4.6.2 Fresenius Kabi Will Continue to Expand
4.7 Pharmstandard - The Largest Russian Pharmaceutical Manufacturer: Company Overview, 2017
4.7.1 Acquisitions Strengthen Pharmstandard Manufacturing and Product Base
4.7.2 Pharmstandard Benefits from Strong Organic Production Capacity
4.7.3 Pharmstandard Generic Drugs Revenue Forecast, 2019-2029
4.8 Gedeon Richter – Hungarian Leader Looking Further Afield: Company Overview, 2017
4.8.1 Female Health and Fertility Segments Form Core Strengths for Gedeon Richter
4.8.2 Specialisation Strategy for Further Growth
4.8.3 A Pan-European Pharmaceutical Presence for the Future?
4.8.4 Gedeon Richter Recent Developments, 2017
4.8.5 Gedeon Richter Generic Drugs Revenue Forecast, 2019-2029
4.9 Krka Pharmaceuticals- Slovenian Generic Giant Active in 70+ Countries: Company Overview, 2017
4.9.1 Prescription Generics: Krka’s Major Focus
4.9.2 Eastern Europe is Still the Largest National Market for Krka
4.9.3 Krka Generic Drugs Revenue Forecast, 2019-2029
4.10 Stada Arzneimittel - Major Presence in Germany and Central Europe: Company Overview, 2017
4.10.1 Germany is the Largest Market for Stada’s Generics Segment
4.10.2 Strong Product Development with Over 670 Product Launches in 2017
4.10.3 Stada Arzneimittel Generic Drugs Revenue Forecast, 2019-2029
4.11 Perrigo: Company Overview, 2017
4.11.1 Perrigo Drives Generic Segment Growth through Acquisitions, but Will it be Acquired Itself?
4.11.2 Rx Pharmaceuticals: Main Contributors to Perrigo’s Revenue Stream
4.12 Polpharma - Poland’s Generic Powerhouse: Company Overview, 2017
4.12.1 Polpharma’s Continuous Product Portfolio Enlargement
4.12.2 Strong Regional Presence in Poland, Russia and Kazakhstan
4.12.3 Acquisition Increases Polpharma Dominance in the Polish Market
4.13 Chemo: New Entrant on the Visiongain European Generics List, Company Overview 2017

5. Top Indian Generic Drug Manufacturers: Activities and Prospects, 2017-2028
5.1 Companies Covered in This Chapter
5.2 India: Generics Supplier to the World
5.3 Top 10 Indian Generic Drug Manufacturers: Financial Performance Outline, 2017
5.4 Sun Pharmaceutical - Leader in the Indian Generic Drug Market, Company Overview, 2017
5.4.1 Sun Has a Leading Presence in the Generic Export Market
5.4.2 Mega Acquisition of Ranbaxy to Enlarge Sun’s Market Share
5.4.3 Sun Pharmaceutical Generic Drugs Revenue Forecast, 2019-2029
5.5 Dr. Reddy’s Laboratories: Company Overview, 2017
5.5.1 At the Forefront of the Indian Generic Boom: Dr. Reddy’s Gerneric Revenue Approaching $2bn in FY2018
5.5.2 North America is the Largest Export Markets for Dr. Reddy’s
5.5.3 Dr. Reddy’s Early Leadership in Biosimilar Antibodies
5.5.4 Dr. Reddy’s Key Developments, 2017
5.5.5 Dr. Reddy’s: Generic Drugs Revenue Forecast, 2019-2029
5.6 Lupin - The Most Successful Indian Generic Firm in the US Market: Company Overview, 2017
5.6.1 Lupin’s Continuous Portfolio Growth and Focus on Complex Injectables
5.6.2 Strong R&D Investment in New Delivery Systems and Original Products
5.6.3 Lupin Generic Drugs Revenue Forecast, 2019-2029
5.7 Cipla - Mumbai Based Generic Giant: Company Overview, 2017
5.7.1 Cipla Targets a US Expansion Through Acquisitions
5.7.2 Cipla’s Leadership in Anti-Retroviral Drugs and Focus on Key Markets
5.7.3 Chronic Disease: A Significant Target for Cipla
5.7.4 Cipla Key Developments, 2017-2018
5.7.5 Cipla Generic Drugs Revenue Forecast, 2019-2029
5.8 Aurobindo – The Largest FDA APIs Supplier, Moved Into Original Drugs: Company Overview, 2017
5.8.1 High-Margin Specialty Generics
5.8.2 ANDA Filings and Approvals, 2017
5.8.3 CRAMS Opportunities
5.9 Glenmark - Specialty Company Still Leveraging Generic Growth: Overview, 2017
5.9.1 Generics Remain Part of Global Growth Strategy for Glenmark
5.9.2 Glenmark Benefits from a Surge in the European Markets
5.9.3 Glenmark Generic Drugs Revenue Forecast, 2019-2029
5.10 Wockhardt -Increasing Presence in US and Europe Generics Market: Company Overview, 2017
5.10.1 US Market Growth in 2017
5.10.2 Biosimilars, Novel Delivery Systems and Original Drugs Will Drive Growth for Wockhardt
5.11 Cadila - Leader in Indian Cardiovascular Market: Company Overview, 2017
5.11.1 Biochem Acquisition Boosts Cadila’s Revenue
5.11.2 Increasing Presence in the US Market
5.11.3 Cadila: A Future Biosimilar Force?
5.12 Ipca Laboratories - One of Top 10 Indian Pharma Exporters: Company Overview, 2017
5.12.1 Fast Development Due to Niche Strategic Approach
5.13 Torrent Pharma Establishes Itself on the Global Generics Market: Company Overview 2017
5.13.1 Domestic and US Expansion Continued in 2017

6. Top Generic Drug Manufacturers from the Rest of the World: Activities and Prospects, 2019-2029

6.1 Companies Covered in this Chapter
6.2 Leading Rest of the World Generic Drug Manufacturers: Financial Performance Outline, 2017
6.3 Japanese and Brazilian Generic Environment Particularly Significant to the Global Generic Drug Market
6.4 Teva Pharmaceutical Industries: Company Overview of the World’s Generic Industry Leader, 2017
6.4.1 Teva Historical Performance and Financial Results Analysis, 2015-2017
6.4.2 Teva Generic Drugs Revenue Forecast, 2019-2029
6.4.3 Teva’s Global Presence
6.4.4 How did Teva Achieve its Success?
6.4.5 Teva Operational Strategy: Focus on Cost Reduction
6.4.6 The US Market Stagnates but Teva Sustains its Strong Penetration
6.4.7 From Volume to Value Driven Strategy in the European Markets
6.4.8 Teva Strengthens its Position in the Central Nervous System Market Through the Acquisition of Auspex Pharma
6.4.9 Teva Acquires Actavis Consolidating Position as the Global Leader
6.4.9.1 Actavis: Company History
6.5 EMS - Leading the South American Generic Market: Company Overview, 2017
6.5.1 First Brazilian Company to Export Generics to Europe
6.5.2 EMS Has the Most Advanced Latin American R&D Base
6.6 Aspen Pharmacare - South African Giant Continues to Expand: Company Overview, 2017
6.6.1 Continuing Dominance in South Africa Generic Market
6.6.2 Asia-Pacific and International Business Main Revenue Contributors in 2017
6.6.3 Europe/CIS and Latin America: Another Major Growth Opportunity for Aspen
6.6.4 Aspen Generic Drugs Revenue Forecast, 2019-2029
6.7 Nichi-Iko: Company Overview, 2017
6.7.1 More Than 900 Generic Products in Nichi-Iko Portfolio
6.7.2 Nichi-Iko Acquires Sagent Pharmaceuticals
6.8 Abdi Ibrahim: Turkey’s Leading Pharmaceutical Company 2017
6.8.1 Large Product Portfolio Helps to Sustain Market Position
6.8.2 Abdi Ibrahim has a Vast International Scope
6.9 Hypermarcas SA - Brazilian Pharmaceutical and OTC Giant: Company Overview, 2017
6.10 Eurofarma - Rapidly-Growing Generics Power in Brazil: Company Overview, 2017
6.10.1 Nine Diversified Business Divisions
6.10.2 M&A Extending Latin American Reach for Eurofarma
6.11 Taro Pharmaceuticals - The Second Largest Israeli Pharmaceutical Manufacturer: Company Overview, 2017
6.11.1 Taro Acquires Zalicus Pharmaceutical in 2015
6.12 Towa Pharmaceuticals - Another Big Japanese Player: Company Overview, 2017
6.12.1 Large Number of Generic Products in Towa’s Portfolio
6.12.2 Towa’s Broad and Expanding Production Capacity
6.13 Sawai Pharmaceuticals - Osaka-Based Generic Leader: Company Overview, 2017
6.13.1 Annual Manufacturing Ambitions to Reach 15 Billion Tablets in 2017
6.13.2 Cardiovascular Drugs are the Most Significant Therapeutic Area for Sawai
6.13.3 M&A Boosts Sawai’s R&D

7. Conclusions
7.1 Companies’ Growth Strategies
7.2 Why are Big Pharma Companies Targeting Generics?
7.3 Big Pharma Business Models Evolve
7.4 Biosimilars Will Have a Transformative Effect on Both Generic and Originator Drug Companies
7.5 Complex Generics with High Entry Barriers Continue to Increase in Importance
7.6 Future Trends for Generic Drug Producers – What’s Possible?

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form

List of Tables
Table 2.1 Top 50 Generic Drug Manufacturers: Global Rank 1-25, Country and Revenues from Generics ($m), 2017
Table 2.2 Top 50 Generic Drug Manufacturers: Global Rank 26-50, Country and Revenues from Generics ($m), 2017
Table 2.3 Top 50 Generic Drug Manufacturers: Revenue ($m) and Market Share (%) According to Group Rank, 2017
Table 2.4 Regional Distribution of the Top 50 Companies, 2017
Table 3.1 Top 10 North American Generic Drug Manufacturers: Revenues ($m) and Ranking, 2017
Table 3.2 Mylan: Company Overview, 2017
Table 3.3 Mylan: Historical Generic Drugs Revenue Estimate ($m), AGR (%), 2013-2017
Table 3.4 Mylan: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 3.5 Pfizer: Company Overview, 2017
Table 3.6 Pfizer: Historical Generic Drugs Revenue Estimate ($m), AGR (%), 2013-2017
Table 3.7 Pfizer: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 3.8 Abbott: Company Overview, 2017
Table 3.9 Abbott: Historical Generic Drugs Revenue Estimate ($m), AGR (%), 2013-2017
Table 3.10 Abbott: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 3.11 Apotex: Company Overview, 2017
Table 3.12 Endo: Company Overview, 2017
Table 3.13 Endo: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 3.14 Valeant: Company Overview, 2017
Table 3.15 Valeant: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 3.16 Pharmascience: Company Overview, 2017
Table 3.17 Mallinckrodt: Company Overview, 2017
Table 3.18 Akorn Pharmaceuticals: Company Overview, 2017
Table 3.19 Alvogen Pharmaceuticals: Company Overview, 2017
Table 3.20 Impax Laboratories: Company Overview, 2017
Table 4.1 Top European Generic Manufacturers: Revenues ($m), 2017
Table 4.2 Novartis (Sandoz): Company Overview, 2017
Table 4.3 Novartis (Sandoz): Historical Generic Drugs Revenues ($m), AGR (%), 2013-2017
Table 4.4 Novartis (Sandoz): Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 4.5 Sanofi: Company Overview, 2017
Table 4.6 Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2013-2017
Table 4.7 Sanofi: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 4.8 Fresenius Kabi: Company Overview, 2017
Table 4.9 Pharmstandard: Company Overview, 2017
Table 4.10 Pharmstandard: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 4.11 Gedeon Richter: Company Overview, 2017
Table 4.12 Gedeon Richter: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 4.13 Krka Pharmaceuticals Company Overview, 2017
Table 4.14 Krka Pharmaceuticals: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 4.15 Stada Arzneimittel Company Overview, 2017
Table 4.16 Stada Arzneimittel Pharmaceuticals: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 4.17 Perrigo: Company Overview, 2017
Table 4.18 Polpharma: Company Overview, 2017
Table 4.19 Chemo: Company Overview, 2017
Table 5.1 Top 10 Indian Generic Manufacturers: Revenues($m) and Ranking, 2017
Table 5.2 Sun Pharmaceutical: Company Overview, 2017
Table 5.3 Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 5.4 Dr. Reddy’s: Company Overview, 2017
Table 5.5 Dr. Reddy’s: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 5.6 Lupin: Company Overview, 2017
Table 5.7 Lupin: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 5.8 Cipla: Company Overview, 2017
Table 5.9 Cipla: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 5.10 Aurobindo: Company Overview, 2017
Table 5.11 Aurobindo: ANDA Filings and Approvals, 2017
Table 5.12 Glenmark: Company Overview, 2017
Table 5.13 Glenmark: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 5.14 Wockhardt: Company Overview, 2017
Table 5.15 Cadila: Company Overview, 2017
Table 5.16 Ipca: Company Overview, 2017
Table 5.17 Torrent Pharma: Company Overview, 2017
Table 6.1 Top 10 Rest of the World Generic Drug Manufacturers, Revenues ($m) and Ranking, 2017
Table 6.2 Teva: Company Overview, 2017
Table 6.3 Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2015-2017
Table 6.4 Teva: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 6.5 EMS: Company Overview, 2017
Table 6.6 Aspen Pharmacare: Company Overview, 2017
Table 6.7 Aspen: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2029
Table 6.8 Nichi-Iko: Company Overview, 2017
Table 6.9 Abdi Ibrahim: Company Overview, 2017
Table 6.10 Hypermarcas: Company Overview, 2017
Table 6.11 Eurofarma: Company Overview, 2017
Table 6.12 Taro Pharmaceutical: Company Overview, 2017
Table 6.13 Towa Pharmaceutical: Company Overview, 2017
Table 6.14 Sawai Pharmaceutical: Company Overview, 2017

List of Figures
Figure 2.1 Top 50 Generic Drug Manufacturers: Revenues ($m), 2017
Figure 2.2 Generic Drug Manufacturers: Revenue ($m) Comparison by Group Rank, 2017
Figure 2.3 Top 50 Generic Drug Manufacturers: Market Share (%) Amongst the Top 50 Companies According to Group Rank, 2017
Figure 2.4 Top 10 Generic Drug Manufacturers: Market Share (%) Among the Top 50 Companies, 2017
Figure 2.5 Regional Balance Among the Top 50 Generic Drug Manufacturers, 2017
Figure 2.6 Biosimilars and Generics: Overview, 2017
Figure 3.1 Top 10 North American Generic Manufacturers: Revenues ($m), 2017
Figure 3.2 Mylan: Historical Generic Drugs Revenue Estimate ($m), AGR (%), 2013-2017
Figure 3.3 Mylan: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 3.4 Mylan: Generic Drugs AGR Forecast (%), 2019-2029
Figure 3.5 Pfizer: Historical Generic Drugs Revenue Estimate ($m), AGR (%), 2013-2017
Figure 3.6 Pfizer: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 3.7 Pfizer: Generic Drugs AGR Forecast (%), 2018-2029
Figure 3.8 Abbott: Historical Generic Drugs Revenue Estimate ($m), AGR (%), 2013-2017
Figure 3.9 Abbott: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 3.10 Abbott: Generic Drugs AGR Forecast (%), 2018-2029
Figure 3.11 Endo: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 3.12 Endo: Generic Drugs AGR Forecast (%), 2018-2029
Figure 3.13 Valeant: Revenue Breakdown by Business Segment, 2017
Figure 3.14 Valeant: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 3.15 Valeant: Generic Drugs AGR Forecast (%), 2018-2029
Figure 3.16 Akorn’s Key Acquisition: Reasons Overview
Figure 4.1 Top 10 European Generic Manufacturers: Revenues ($m), 2017
Figure 4.2 Novartis: Revenue Breakdown by Business Segment, 2017
Figure 4.3 Novartis (Sandoz): Historical Generic Drugs Revenues ($m), AGR (%), 2013-2017
Figure 4.4 Novartis (Sandoz): Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 4.5 Novartis (Sandoz): Generic Drugs AGR Forecast (%), 2018-2029
Figure 4.6 Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2013-2017
Figure 4.7 Sanofi: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 4.8 Sanofi: Generic Drugs AGR Forecast (%), 2018-2029
Figure 4.9 Pharmstandard: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 4.10 Pharmstandard: Generic Drugs AGR Forecast (%), 2018-2029
Figure 4.11 Gedeon Richter: Revenue Breakdown by Therapeutic Segment, 2017
Figure 4.12 Gedeon Richter: Geographical Revenue Breakdown, 2017
Figure 4.13 Gedeon Richter: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 4.14 Gedeon Richter: Generic Drugs AGR Forecast (%), 2019-2029
Figure 4.15 Krka Pharmaceuticals: Revenue Breakdown by Business Segment, 2017
Figure 4.16 Krka Pharmaceuticals: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 4.17 Krka Pharmaceuticals: Generic Drugs AGR Forecast (%), 2019-2029
Figure 4.18 Stada: Revenue Breakdown (%) by Business Segment, 2017
Figure 4.19 Stada: Top 8 Generic Markets by Revenue, 2017
Figure 4.20 Stada Arzneimittel: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 4.21 Stada Arzneimittel: Generic Drugs AGR Forecast (%), 2018-2029
Figure 5.1 Top Indian Generic Manufacturers: Revenues ($m), 2017
Figure 5.2 Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 5.3 Sun Pharmaceutical: Generic Drugs AGR Forecast (%), 2018-2029
Figure 5.4 Dr. Reddy’s: Revenue Breakdown by Business Segment, 2017
Figure 5.5 Dr. Reddy’s: Revenue Breakdown by Region, 2017
Figure 5.6 Dr. Reddy’s: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 5.7 Dr. Reddy’s: Generic Drugs AGR Forecast (%), 2018-2029
Figure 5.8 Lupin: Revenue Breakdown by Markets, 2017
Figure 5.9 Lupin: Revenue Breakdown by Therapeutic Area, 2017
Figure 5.10 Lupin: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 5.11 Lupin: Generic Drugs AGR Forecast (%), 2018-2029
Figure 5.12 Cipla: Revenue Breakdown by Region, 2017
Figure 5.13 Cipla: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 5.14 Cipla: Generic Drugs AGR Forecast (%), 2018-2029
Figure 5.15 Glenmark: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 5.16 Glenmark: Generic Drugs AGR Forecast (%), 2018-2029
Figure 5.17 Wockhardt: Revenue Breakdown by Region, 2017
Figure 5.18 Ipca: Export Revenue Breakdown by Region, 2017
Figure 6.1 Top 10 Rest of the World Generic Manufacturers: Revenues ($m), 2017
Figure 6.2 Teva: Revenue Breakdown by Business Segment, 2017
Figure 6.3 Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2015-2017
Figure 6.4 Teva: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 6.5 Teva: Generic Drugs AGR Forecast (%), 2018-2029
Figure 6.6 Teva: Revenue Breakdown by Region, 2017
Figure 6.7 Aspen: Revenue Breakdown (%) by Region, 2017
Figure 6.8 Aspen: Generic Drugs Revenue Forecast ($m), 2017-2029
Figure 6.9 Aspen: Generic Drugs AGR Forecast (%), 2018-2029
Figure 7.1 Top 10 Generic Drug Manufacturers: Market Share (%) Among the Top 50 Companies, 2017
Figure 7.2 Regional Balance Among the Top 50 Generic Drug Manufacturers, 2017
Abbott
AbbVie
Abdi Ibrahim
Ache
Acino Pharma AG
Actavis
Adcock Ingram
Advance Vision Research
Agouron Pharmaceuticals
Akorn
Alcon
Allergan
Altaris Capital Partners
Alvogen
Amgen
Amneal Pharmaceuticals LLC
Amneal Pharmaceuticals, Inc.
Anchen Pharmaceuticals
APIs manufacturers Gujarat Lyka Organics
ApoPharma
Apotex
Apotex Australia
Apotex Fermentation
APP Pharmaceuticals
Aprogen
Arrow Pharmaceuticals
Asahi Kasei Pharma Corporation
Aspen
Aspen Health Care
Aspen Pharma
Aspen Trading
Aurigene Discovery Technologies
Aurobindo
Auspex Pharma
Aventis
Barr Pharmaceuticals
Bausch & Lomb
Bausch and Lomb Holdings Inc.
Bayer
Bayer Yakuhin
Bever Pharmaceutical Pte Ltd
Biocad Holding Ltd.
Bioceros
Biochem Pharma
Biocraft Laboratories
Bioniche Pharma
Biosintez
Biovail Corporation
Boca Pharmacal
Boehringer Ingelheim
Bremer Pharma
Bunker
Cadila Healthcare
Celltrion
Cenova Pharma
Cephalon
CFR Pharmaceuticals
Chattem Chemicals
Chemo Group
Chimpharm
Chiron Corporation
Chirotech Technology
CIBA VISION
Ciba-Geigy
Cipla
Claris
CNS Therapeutics
CSPC Pharma
CXP Pharmaceuticals
Dabur Pharma
DACA Pharmaceuticals
Daichi Kasei Co.
Delta
Dialfor Health
Dr. Reddy's Laboratories
DreamPharma
DuPont Merck
Dusa Pharmaceuticals
DUSA Pharmaceuticals
Ebewe
Elan Pharmaceuticals
Elder Pharmaceuticals
Emergent Biosolutions
Emploi Quebec
EMS
EMS Consumer
EMS Generics
EMS Hospital
EMS Sigma Pharma
EMS Similars
Endo Pharmaceuticals
Eon Labs
EPD Business
Ethics Bio Lab
Eurofarma
European Medicines Agency (EMA)
Facet Biotech
Fenwal
Fera Pharmaceuticals
Filaxis
Food and Drug Administration (FDA)
Forest Laboratories
Fougera Pharmaceuticals
Fresenius Kabi
Fuso Pharmaceutical
Fuso Pharmaceutical Industries
G. D. Searle & Company
Gangene Corp
Gedeon Richter
Genfar S.A.
Germa Pharm
GlaxoSmithKline (GSK)
Glenmark
Glenmark Generics Limited
Golden Cross Pharma
Graceway Pharmaceuticals
Greenstone
Grunenthal
Handok
Herbapol Pruszkow
Heumann Pharma
Hexal
Hikma
Hisun-Pfizer Pharmaceuticals
Hi-Tech Pharmacal
Hi-Tech Pharmaceuticals
Hormosan Pharma
Hospira
Hungarian State Holding Company
Hypermarcas
Hypermarcas SA
IDEV Technologies
Ikaria, Inc.
Impax
Impax Laboratories
InfaCare Pharmaceutical Corporation
Innopharma
Inspire Pharmaceuticals
Insud Pharma
InvaGEn Pharmaceuticals Inc
Investissement Quebec
Ipca
Jai Pharma Limited
J-DOLPH Pharmaceutical Co.
Johnson & Johnson
JPH Group Holdings
Kaken Shoyaku
Kilitch Drugs
KM Godo Kaisha
Kobrek Pharmaceuticals
Krka
Krka Group
Kunwha Pharmaceuticals
KV Pharmaceuticals
Labesfal
Laboratorio Sanderson
Laboratorio Teuto Brasileiro
Laboratorios Gautier
Laboratorios Grin
Laboratorios Kendrick
Lannett
LEk
Lekko
Les Laboratories Servier
Litha
Lotus Pharmaceutical
Lupin
mAbxience
Madaus
Mallinckrodt
Mallinkrodt
Masterlek
Matrix Laboratories
Mechnikov Biomed
Meda
Mediate Specialities
Medisa Shinyaku
Medivation
Medley Industria Farmaceutica
Medquímica Indústria Farmacêutica LTDA
Meiji Seika Pharma
Meiji Upsher-Smith Laboratories
Merck KGaA
Microdose
Milmet Labs
Mitsubishi Tanabe Pharma
MJ Pharma
Morton Grove Pharmaceuticals
Multicare Pharmaceuticals
Mylan
Mylan Laboratories
Mylan Pharmaceuticals
Mylan Specialty
Mylan Technologies Inc.
NATCO Pharma Limited
National Druggists
NBZ Pharma Limited
Neupoge
Nichi-Iko
Nichi-Iko Pharma Tech
Nicox
Nippon Chemiphar
Nippon Kayaku
NIXS Corporaration
Novartis
Novartis (Sandoz)
Novel Laboratories
Nycomed
Oak Pharmaceuticals
Ocera Therapeutics
OctoPlus
Omega Pharma
Onyx
OptiMedica
Oriel Therapeutics
Orion
Paladin Labs
Par Pharma
Par Pharmaceuticals
Parke-Davis
Pendopharm
Perrigo
Perrigo Company
Pfizer
PGT Healthcare
Pharma Dynamics
Pharmascience
Pharmstandard
Pharmstandard Biotec
Phlox Pharma
Pinewood Laboratories
Piramal Healthcare Solutions
Polfa Warszawa
Polpharma
Pradeep Drug Company
Promius Pharma
Pymepharco
Qualitest
Quesada Pharmaceutical
Ranbaxy Laboratories
Ratiopharm
Renaissance
Ribbon
Richter-Helm
Roemmer
Rx Pharmaceuticals
Sabex
Sagent Pharmaceuticals
Salix Pharmaceuticals
Sandoz
Sanofi
Santa Catharina pharmacy
Sawai Pharmaceutical
Sekisui Medical
Sigma Pharmaceuticals
Solvay Pharmaceuticals
Spirig Pharma
St Jude Medical
Stada
Stada Arzneimittel
STARLIMS
Strides Arcolab
Sucampo Pharmaceuticals, Inc.
Sun Pharmaceuticals
Swisse Wellness
Synthelabo
Taiyo
Taro Pharmaceuticals
Temmler Pharma GmbH & CO. KG
Teuto Brasileiro
Teva
Torrent do Brasil
Torrent Pharma
Torrent Pharma Inc.
Towa Pharmaceutical
Tower Holdings
UDL Laboratories
United Research Laboratories
URL Pharma
Valeant Pharmaceuticals
Veropharm
VersaPharm Incorporated
Vindexpharm
Volta and Farmindustria
VPI Holdings Corp
Warner Chilcott
Warner Lambert
Wockhardt
Wyeth
Yakuhan Pharmaceuticals
Zalicus Pharmaceutical
Zao Sun Pharma
Zao Torrent
Zhejiang Hisun Pharmaceutical
Zoetis
Zydus Pharmaceuticals
Zydus Wellness
Zyg Pharma Private Limited

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029


facebookWin a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.

Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/

Would you like a free report overview of the report of your choice?

If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com

Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?

What are the dynamic growth sectors? where are the regional business opportunities?

Which technologies will prevail and who are the leading companies succeeding in these sectors and why?

If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.

If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987

  • Human Microbiome Therapeutics Market 2019-2029
  • Top 20 Urology Companies 2019
  • Global Antidepressant and Anti-Anxiety Drugs Market Forecasts 2019-2029
  • The Top 100 In-Vitro Diagnostics Companies to Watch 2019
  • Global Hypertension Drugs Market 2019-2029
  • The Next Generation Sequencing Market 2019-2029
  • Lyophilisation for Pharmaceuticals: Products and Services 2019-2029
  • Top 25 In Vitro Diagnostics (IVD) Companies 2019
  • Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2019-2029
  • Global Biomarkets and Technologies Market 2019-2029
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Kuwait Pharmaceutical Association
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Generic Medicines Association
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Latest Pharma news

“In 2017, the Top 5 Vaccines Manufacturers held 76% of the Global Vaccines Market” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs.

12 February 2019

READ

“Translational Regenerative Medicine market set to grow to $76bn by 2023” says new Visiongain report

Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific.

07 February 2019

READ

“Global Pre-Filled Syringes market set to grow to $19bn by 2024” says new Visiongain report

The market is expected to grow strongly driven by numerous trends in the overall pharmaceutical market, such as more self-administration of medicines, the development of biological drugs and biosimilars, and the increasing burden of chronic diseases such as diabetes and high cholesterol.

31 January 2019

READ

“30% of the Top Generic Drug Producers are in the ROW region” says new Visiongain report

This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017.

31 January 2019

READ

Categories

Category